Office-based therapies for benign prostatic hyperplasia: a review and update.

CONCLUSIONS: Both the UroLift and Rezum are minimally invasive treatment options capable of providing rapid, significant and durable relief of LUTS secondary to BPH. They demonstrate comparable efficacy to TURP with the added advantage of preserving sexual function and decreasing patient morbidity and healthcare costs. PMID: 31481142 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31481142?dopt=Abstract

Source: Canadian Journal of Urology - September 6, 2019 Category: Urology & Nephrology Tags: Can J Urol Source Type: research